BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34971338)

  • 1. In silico bioprospecting of antiviral compounds from marine fungi and mushroom for rapid development of nutraceuticals against SARS-CoV-2.
    Srivastav AK; Jaiswal J; Kumar U
    J Biomol Struct Dyn; 2023 Mar; 41(5):1574-1585. PubMed ID: 34971338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plant derived active compounds as potential anti SARS-CoV-2 agents: an
    Kashyap D; Jakhmola S; Tiwari D; Kumar R; Moorthy NSHN; Elangovan M; BrĂ¡s NF; Jha HC
    J Biomol Struct Dyn; 2022; 40(21):10629-10650. PubMed ID: 34225565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
    Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Erdogan T
    J Biomol Struct Dyn; 2023 Apr; 41(6):2448-2465. PubMed ID: 35088655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
    Tatar G; Salmanli M; Dogru Y; Tuzuner T
    J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking and simulation studies of natural compounds of
    Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An
    Rangsinth P; Sillapachaiyaporn C; Nilkhet S; Tencomnao T; Ung AT; Chuchawankul S
    J Tradit Complement Med; 2021 Mar; 11(2):158-172. PubMed ID: 33520685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cameroonian medicinal plants as potential candidates of SARS-CoV-2 inhibitors.
    Fouedjou RT; Chtita S; Bakhouch M; Belaidi S; Ouassaf M; Djoumbissie LA; Tapondjou LA; Abul Qais F
    J Biomol Struct Dyn; 2022; 40(19):8615-8629. PubMed ID: 33908318
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
    J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation.
    Daoud I; Mesli F; Melkemi N; Ghalem S; Salah T
    J Biomol Struct Dyn; 2022; 40(23):12574-12591. PubMed ID: 34541995
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Chandra A; Chaudhary M; Qamar I; Singh N; Nain V
    J Biomol Struct Dyn; 2022 Sep; 40(14):6534-6544. PubMed ID: 33583328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery.
    Arunkumar M; Gunaseelan S; Kubendran Aravind M; Mohankumar V; Anupam P; Harikrishnan M; Siva A; Ashokkumar B; Varalakshmi P
    J Biomol Struct Dyn; 2022; 40(19):8961-8988. PubMed ID: 34014150
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kumar B; Parasuraman P; Murthy TPK; Murahari M; Chandramohan V
    J Biomol Struct Dyn; 2022 Oct; 40(17):7796-7814. PubMed ID: 33759690
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.